Plant and Equipment US$m Right-of-use assets US$m Capital work in progress US$m Total US$m 2022 2021 2022 2021 2022 2021 2022 2021 4,078.4 3,603.4 1,848.8 1,587.6 3,081.6 3,627.8 11,460.6 10,368.6 (2,116.1) (1,936.3) (556.8) (485.9) – – (3,152.0) (2,832.6) 1,962.3 1,667.1 1,292.0 1,101.7 3,081.6 3,627.8 8,308.6 7,536.0 1,667.1 1,588.3 1,101.7 939.4 3,627.8 2,852.5 7,536.0 6,305.4 614.6 266.5 – – (1,550.4) (502.6) – 0.9 9.7 49.0 301.0 238.8 1,083.6 1,318.5 1,397.4 1,610.0 (4.4) (4.1) (0.2) – (1.6) (8.1) (11.5) (12.3) (277.5) (272.4) (90.5) (77.1) – – (445.7) (399.4) – – – – (13.2) (74.4) (13.2) (74.4) (47.2) 39.8 (20.0) 0.6 (64.6) 41.9 (154.4) 105.8 1,962.3 1,667.1 1,292.0 1,101.7 3,081.6 3,627.8 8,308.6 7,536.0 Right-of-use (“ROU”) assets The Group primarily has leases for plasma centres, office buildings, warehouses, land and vehicles. Except for short-term leases and leases of low value assets, the Group recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). The Group accounting policy for lease liabilities has been discussed in Note 11(d). Unless the Group is reasonably certain to obtain ownership of the underlying asset at the end of the lease term, the recognised right-of-use assets are depreciated on a straightline basis over the shorter of its estimated useful life and the lease term. Other arrangements In May 2020, CSL entered into a strategic partnership with Thermo Fisher Scientific (“TFS”) which included a lease of a recombinant protein facility in Lengnau. The lease commenced during the year ended 30 June 2022 and has a 20 year term with two five year extension options. The lease has been accounted for as an operating lease and the leased property, plant and equipment continue to be presented in the balance sheet. The total future operating lease payments receivable from TFS (excluding extension options) were $454.1m at 30 June 2022. CSL Limited Annual Report 2021/22 117
RkJQdWJsaXNoZXIy MjE2NDg3